Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px
Document › Details

GlaxoSmithKline plc. (12/16/19). "Press Release: Pivotal DREAMM-2 Study Demonstrated a Clinically Meaningful Overall Response Rate with Belantamab Mafodotin (GSK2857916) for Patients with relapsed/refractory Multiple Myeloma". London.

Region Region United States (USA)
Organisations Organisation GlaxoSmithKline plc (LSE: GSK, NYSE: GSK)
  Group GlaxoSmithKline (GSK) (Group)
  Organisation 2 Emory University
Products Product belantamab mafodotin (GSK2857916)
  Product 2 clinical research
Person Person Barron, Hal (GSK 201801– CSO before Alphabet (Calicio) + Roche/Genentech)
     


   
Record changed: 2020-01-13

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for GlaxoSmithKline (GSK) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top